Last reviewed · How we verify

Fluorouracil/Calcipotriene — Competitive Intelligence Brief

Fluorouracil/Calcipotriene (Fluorouracil/Calcipotriene) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite + Vitamin D analog combination. Area: Oncology.

phase 3 Antimetabolite + Vitamin D analog combination Thymidylate synthase; Vitamin D receptor (VDR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fluorouracil/Calcipotriene (Fluorouracil/Calcipotriene) — M.D. Anderson Cancer Center. Fluorouracil inhibits thymidylate synthase to disrupt DNA synthesis, while calcipotriene promotes keratinocyte differentiation and immune modulation for topical anticancer effect.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fluorouracil/Calcipotriene TARGET Fluorouracil/Calcipotriene M.D. Anderson Cancer Center phase 3 Antimetabolite + Vitamin D analog combination Thymidylate synthase; Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite + Vitamin D analog combination class)

  1. M.D. Anderson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluorouracil/Calcipotriene — Competitive Intelligence Brief. https://druglandscape.com/ci/fluorouracil-calcipotriene. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: